Proactive Investors - Run By Investors For Investors

Shield Therapeutics CEO delighted with further positive results from pivotal Feraccru study

Carl Sterritt, chief executive of Shield Therapeutics PLC (LON:STX), tells Proactive London's Andrew Scott their iron deficiency treatment Feraccru delivered strong benefits for people with kidney-related anaemia in an extended trial.

The 52-week open-label study showed increased haemoglobin levels in both those taking it for the whole period and also in those who switched from the placebo after the first 16-weeks.

 
Meet Faron Pharmaceuticals Ltd, Belvoir Lettings, Silence Therapeutics PLC, ANGLE PLC and ReNeuron Group PLC at our event, London , 23 May 2019. Register here »
View full STX profile View Profile

Shield Therapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use